MINPP1 decreases the number of hepatocellular carcinoma cells via this glycolytic bypass, and it is believed that, in the future, this molecule will emerge as a synergistic drug target for hepatocellular carcinoma therapeutics. This evidence concerns the gene MINPP1 and hepatocellular carcinoma.